Dopamine News and Research

Latest Dopamine News and Research

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

13 Mar 2012

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

TSRI, OPKO Health to develop and commercialize SR 3306 for Parkinson's

OPKO Health, Inc. and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

BioLineRx receives European patent for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a European patent has been granted claiming BL-1020's composition and its use for the treatment of schizophrenia.

8 Mar 2012

Parkinson's drug Amantadine may help brain injury victims: Study

The study shows that Amantadine helps boost brain levels of dopamine, a neurotransmitter linked to arousal. And for patients who are in a vegetative state following a brain injury, the drug can help -- possibly by improving responsiveness during rehabilitation.

1 Mar 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012

New drug for Huntington's disease might operate via previously unknown mechanisms of action

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease - pridopidine or dopamine stabiliser ACR16 - might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival.

24 Feb 2012

New Huntington's drug might operate via previously unknown mechanisms of action

24 Feb 2012

Dopamine therapy can boost creativity in patients with Parkinson's

Some Parkinson's Disease patients can suddenly become creative when they take dopamine therapy, producing pictures, sculptures, novels and poetry. But their new-found interests can become so overwhelming that they ignore other aspects of their everyday life, such as daily chores and social activities, according to research published in the March issue of the European Journal of Neurology.

24 Feb 2012

Bath salts mimic effects of two powerful narcotics

The street drug commonly referred to as "bath salts" is one of a growing list of synthetic and unevenly regulated narcotics that are found across the United States and on the Internet. New research on this potent drug paints an alarming picture, revealing that bath salts pack a powerful double punch, producing combined effects similar to both methamphetamine (METH) and cocaine.

24 Feb 2012

Tai chi could benefit Parkinson’s disease patients

A new study found that a six-month program of Tai Chi exercises helped people with various stages of Parkinson's disease improve stability, their ability to walk and reduced the frequency of falls.

12 Feb 2012

Parkinson’s disease gene - parkin explored: Study

Researchers at the University at Buffalo have discovered how mutations in the parkin gene cause Parkinson's disease, which afflicts at least 500,000 Americans and for which there is no cure. The results are published in the current issue of Nature Communications.

9 Feb 2012

Scientists reveal how psychostimulant drugs work to control hyperactivity

It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate - known by the trade names Ritalin, Concerta, and Methylin - and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder.

8 Feb 2012

Researchers discover how mutations in parkin gene cause PD

Parkinson's disease researchers at the University at Buffalo have discovered how mutations in the parkin gene cause the disease, which afflicts at least 500,000 Americans and for which there is no cure.

8 Feb 2012

Study to understand how brain processes information in competitive settings

Researchers have found a way to study how our brains assess the behavior - and likely future actions - of others during competitive social interactions. Their study, described in a paper in the Proceedings of the National Academy of Sciences, is the first to use a computational approach to tease out differing patterns of brain activity during these interactions, the researchers report.

7 Feb 2012

BPS Annual Meeting to be held Feb. 25 - 29 in San Diego

The latest news and discoveries in medicine, physics, environmental science, and interdisciplinary fields will be featured at the 56th Annual Meeting of the Biophysical Society (BPS), held Feb. 25 - Feb. 29, 2012, at the San Diego Convention Center in San Diego, Calif. With more than 4,000 poster presentations, 200 exhibits, 20 symposia, and 6,000 research scientists in attendance each year, the BPS Annual Meeting is the largest meeting of biophysicists in the world.

7 Feb 2012

Scientists evaluate growth, differentiation and function of iPSC-derived NPCs in PD

Induced pluripotent stem cells (iPSC) are a promising avenue for cell replacement therapy in neurologic diseases. For example, mouse and human iPSCs have been used to generate dopaminergic (DA) neurons that improve symptoms in rat Parkinson's disease models. Reporting in the current issue of the Journal of Parkinson's Disease, a group of scientists from Japan evaluated the growth, differentiation, and function of human-derived iPSC-derived neural progenitor cells (NPCs) in a primate model, elucidating their therapeutic potential.

25 Jan 2012

Alexithymia associated with depression in de novo PD patients

Alexithymia has been found to be strongly associated with depression in both general and clinical populations. Alexithymic and depressive symptoms may be partially overlapping, but not all are correlated with depressive symptoms, thus underlining the relative independence of the two disorders. Parkinson's disease (PD) is a clinical condition often characterized by depression and an altered emotional processing. In medicated PD patients alexithymia has a prevalence of 21% and is related to depression.

23 Jan 2012

Research on neuron interaction could lead to potential treatment for addiction

Harvard scientists have developed the fullest picture yet of how neurons in the brain interact to reinforce behaviors ranging from learning to drug use, a finding that might open the door to possible breakthroughs in the treatment of addiction.

19 Jan 2012

Alcohol-dependent Americans more likely to seek treatment than South Koreans

Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have begun to see a steady increase in alcohol use and have entered the early stages of a tobacco epidemic. A study of alcohol use disorders (AUDs), nicotine dependence (ND), and mood and anxiety disorders in the United States and South Korea has found that while AUDs are substantially more common among Americans than South Koreans, alcohol-dependent Americans are significantly more likely to seek treatment.

17 Jan 2012